On June 30, 2023, INTELLIA THERAPEUTICS ($NASDAQ:NTLA) released their second quarter earnings results for FY2023. Total revenue was USD 13.6 million, a 3.1% decline compared to the same quarter in the previous year. Net income was reported at USD -123.7 million, a decrease of -23 million year-over-year.
On Thursday, INTELLIA THERAPEUTICS stock opened at $38.3 and closed at $39.1, declining 1.6% from its previous closing price of $39.7. In its second quarter report, INTELLIA THERAPEUTICS also highlighted key accomplishments such as new clinical trials initiated for its gene editing technology and new partnerships with industry-leading companies to develop treatments in various therapeutic areas. INTELLIA THERAPEUTICS also announced a new collaboration with a pharmaceutical company to develop potential treatments for certain types of cancer.
INTELLIA THERAPEUTICS is confident that it will continue to generate strong revenue growth and profitability in the future due to its strategic investments in research and development and healthcare partnerships. It is expected that the company will continue to remain focused on developing treatments that use gene editing technology to treat a variety of conditions and diseases. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Intellia Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Intellia Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Intellia Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Intellia Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale is the perfect tool for analyzing INTELLIA THERAPEUTICS‘s fundamentals. Our Risk Rating indicates that INTELLIA THERAPEUTICS is a high risk investment in terms of financial and business aspects. To help you assess the potential risks, GoodWhale has detected 3 risk warnings in the balance sheet, cashflow statement, and non-financial areas. Make sure to register on goodwhale.com to get a full overview of the risks associated with investing in INTELLIA THERAPEUTICS. More…
Risk Rating Analysis
Star Chart Analysis
The company was founded in 2014 and is based in Cambridge, Massachusetts. Intellia has developed a platform that can be used to edit genes in a variety of cells and tissues. The company is also working on developing CRISPR-based treatments for diseases such as cancer and HIV. Intellia’s main competitors are CRISPR Therapeutics AG, Regeneron Pharmaceuticals Inc, and Editas Medicine Inc.
– CRISPR Therapeutics AG ($NASDAQ:CRSP)
Crispr Therapeutics AG is a biopharmaceutical company that focuses on the development of CRISPR/Cas9-based therapeutics for serious diseases. The company’s market cap as of 2022 is 4.28B and its ROE is -18.27%. Crispr Therapeutics AG was founded in 2013 and is headquartered in Zug, Switzerland.
– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)
Regeneron Pharmaceuticals Inc is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company’s products include EYLEA, Praluent, Dupixent, Libtayo, and Kevzara. As of 2021, the company had a market cap of $80.72 billion and a return on equity of 19.7%. Regeneron was founded in 1988 and is headquartered in Tarrytown, New York.
Editas Medicine Inc is a genome editing company based in Cambridge, Massachusetts. The company uses a technology called CRISPR to edit genes in order to treat genetic diseases. As of 2022, Editas Medicine Inc has a market cap of 886.02M and a Return on Equity of -23.75%. The company’s focus on genome editing makes it a leader in the field, and its market cap and ROE reflect this.
INTELLIA THERAPEUTICS recently reported their second quarter earnings results for FY2023. Total revenue was USD 13.6 million, a decrease of 3.1% compared to the same period a year ago. Net income for the quarter was USD -123.7 million, a decrease of -23 million from the same quarter a year ago. This result suggests that investors should be cautious when considering investing in INTELLIA THERAPEUTICS.
Investors should analyze the company’s financial performance, competitive landscape, and outlook before investing to gain a better understanding of the company’s future prospects and performance. Ultimately, investors will need to determine if INTELLIA THERAPEUTICS is a good long-term investment opportunity.